Compare Stocks → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRBUNASDAQ:FMTXNASDAQ:HLVXNASDAQ:ICVXNASDAQ:MGTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$5.14+0.4%$6.37$3.44▼$8.59$464.25M2.591.83 million shs1.35 million shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsHLVXHilleVax$16.63+6.5%$16.22$9.94▼$20.22$826.53M0.68117,499 shs217,270 shsICVXIcosavax$15.31$15.31$4.75▼$16.10$766.88M1.281.22 million shsN/AMGTXMeiraGTx$6.07-2.3%$6.25$3.49▼$8.35$389.82M1.3149,523 shs175,327 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences+0.39%-2.10%-37.77%-10.30%-0.58%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%HLVXHilleVax+6.47%+4.79%-4.48%+3.61%+0.36%ICVXIcosavax0.00%0.00%0.00%-2.86%+141.86%MGTXMeiraGTx-2.25%-6.04%-1.46%-13.53%+15.40%Your $200 account credit is about to expire (Ad)Update to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial HereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBUCaribou Biosciences1.5349 of 5 stars3.41.00.00.03.81.70.0FMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHLVXHilleVax2.8403 of 5 stars3.53.00.00.02.54.20.0ICVXIcosavaxN/AN/AN/AN/AN/AN/AN/AN/AMGTXMeiraGTx4.6252 of 5 stars3.54.00.04.83.31.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences2.75Moderate Buy$22.50337.74% UpsideFMTXForma TherapeuticsN/AN/AN/AN/AHLVXHilleVax3.00Buy$30.6784.41% UpsideICVXIcosavax2.33Hold$26.5073.09% UpsideMGTXMeiraGTx3.00Buy$25.67322.84% UpsideCurrent Analyst RatingsLatest MGTX, ICVX, FMTX, HLVX, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.003/19/2024CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $24.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.001/2/2024ICVXIcosavaxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$34.48M13.46N/AN/A$4.17 per share1.23FMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90HLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/AICVXIcosavax$580K1,322.20N/AN/A$5.47 per share2.80MGTXMeiraGTx$14.02M27.80N/AN/A$2.17 per share2.80Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$102.07M-$1.45N/AN/AN/A-296.05%-31.06%-25.73%5/14/2024 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/AHLVXHilleVax-$123.57M-$3.04N/AN/AN/AN/A-48.17%-38.05%5/10/2024 (Estimated)ICVXIcosavax-$91.76M-$2.22N/AN/AN/AN/A-43.06%-39.53%4/4/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A6.74N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AICVXIcosavaxN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A11.9711.97FMTXForma TherapeuticsN/A12.7412.74HLVXHilleVax0.1010.6210.62ICVXIcosavaxN/A18.0618.06MGTXMeiraGTx0.622.382.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%FMTXForma Therapeutics87.39%HLVXHilleVax86.42%ICVXIcosavax92.59%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences9.50%FMTXForma Therapeutics5.79%HLVXHilleVax29.30%ICVXIcosavax30.59%MGTXMeiraGTx9.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences13790.32 million81.74 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionableHLVXHilleVax6249.70 million35.14 millionNot OptionableICVXIcosavax6050.09 million34.77 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableMGTX, ICVX, FMTX, HLVX, and CRBU HeadlinesSourceHeadlineCARGO Therapeutics (NASDAQ:CRGX) & MeiraGTx (NASDAQ:MGTX) Financial Comparisonamericanbankingnews.com - March 19 at 5:06 AMRoyal Bank of Canada Reiterates "Outperform" Rating for MeiraGTx (NASDAQ:MGTX)americanbankingnews.com - March 19 at 4:24 AMMeiraGTx (NASDAQ:MGTX) Given "Outperform" Rating at Royal Bank of Canadamarketbeat.com - March 18 at 6:34 PMMGTX Apr 2024 12.500 callfinance.yahoo.com - March 17 at 2:29 AMBuy Rating Affirmed: Meiragtx Holdings’ Promising Pipeline and Strategic Partnerships Set Stage for Growthmarkets.businessinsider.com - March 15 at 11:23 PMMGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023investorplace.com - March 14 at 10:03 PMRecap: MeiraGTx Hldgs Q4 Earningsbenzinga.com - March 14 at 8:49 PMMeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023hk.finance.yahoo.com - March 14 at 3:48 PMMeira Retreats on Financial Figuresbaystreet.ca - March 14 at 10:48 AMMeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimateszacks.com - March 14 at 10:46 AMMeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updatesglobenewswire.com - March 14 at 8:30 AMMeiraGTx Holdings plc (NASDAQ:MGTX) stock most popular amongst private equity firms who own 28%, while individual investors hold 26%finance.yahoo.com - February 26 at 1:35 PMMGTX Mar 2024 12.500 callfinance.yahoo.com - February 17 at 10:20 AMMeiraGTx: Bota-Vec Program Advancing With Milestones Being Metseekingalpha.com - February 16 at 6:38 PMMeiraGTx Holdings PLC MGTXmorningstar.com - February 15 at 8:13 PMMeiraGTx Holdings: Other Events, Financial Statements And Exhibitscbonds.com - February 15 at 10:12 AMMeiraGTx receives $50 million milestone payment from Janssenthepharmaletter.com - February 14 at 7:52 AMMeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticalsfinance.yahoo.com - February 13 at 10:56 AMWall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Betfinance.yahoo.com - January 10 at 4:20 PMMeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisionsfinance.yahoo.com - January 10 at 11:20 AMWall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Tradefinance.yahoo.com - December 25 at 1:49 PMMeiraGTx Hldgs Stock (NASDAQ:MGTX), Short Interest Reportbenzinga.com - December 24 at 8:21 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)markets.businessinsider.com - December 23 at 12:00 AMMeiraGTx Hldgs Stock (NASDAQ:MGTX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 7:00 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCaribou BiosciencesNASDAQ:CRBUCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Forma TherapeuticsNASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.HilleVaxNASDAQ:HLVXHilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.IcosavaxNASDAQ:ICVXIcosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.